Skip to content
PAD
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
PAD
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
Search
Read about Endologix
in the news
Embrace the evidence.
The Latest:
May 7
Endologix Announces Appointment of Steve Deitsch to Board of Directors
See Release
All News
Archives
All
2026
2025
2024
2023
2022
2021
Jun 15
Endologix Announces 24-Month Results of DETOUR- 2 Study at 2023 Vascular Annual Meeting
Jun 8
Endologix receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD.
May 23
Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial
May 5
Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program
Apr 27
Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
